Overview

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
Phase:
PHASE3
Details
Lead Sponsor:
Fujian Shengdi Pharmaceutical Co., Ltd.